RoboSense Wins GOLD 2019 Stevie Award
RoboSense (Suteng Innovation Technology Co., Ltd) www.robosense.ai, a leader in LiDAR perception technology solutions, announced today that it has won the GOLD 2019 Stevie ® Award in the “Transportation Category” for the RoboSense Automotive Grade MEMS LiDAR Perception System. The award will be given out at the 17 th Annual Stevie Awards - American Business Awards ® , to be held in NY City on June 11, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190507005708/en/
RS-LiDAR-M1, RoboSense Automotive Grade MEMS LiDAR Perception System's Sensor (Photo: Business Wire)
The RoboSense Automotive Grade MEMS LiDAR Perception System is a revolutionary automotive solution that makes autonomous driving safer, easily mass produced, and lower cost. In addition to the Stevie Award, the RoboSense system is a CES 2019 Innovation Award winner. The system includes automotive grade MEMS solid-state LiDAR RS-LiDAR-M1 and RoboSense’s unique perception RS-LiDAR-Algorithms for a complete system that lets the vehicle understand the road environment for safer autonomous driving. RoboSense’s system offers ground-breaking mass production-ready hardware and software based vehicle environmental perception to support Level 3 to Level 5 autonomous driving at a fraction of the cost.
In preparation for autonomous vehicle mass market growth, RoboSense recently launched the Smart Sensor System (SSS), which combines RoboSense LiDAR sensors, AI point cloud algorithms, and an IC design for chip development. Created for four key smart transportation vehicle applications: autonomous passenger cars, low-speed autonomous vehicles, high-speed RoboTaxis, and V2R (Vehicle to Road infrastructure), the RoboSense Smart Sensor System is a smarter information interpreter that collects and interprets environmental information in one-stop for safer and more intelligent autonomous driving.
Stevie Award Judges Say RoboSense System “will take autonomous driving to the next level” “Impressive product with great growth potential”
A Stevie Award judge said the “MEMS LiDAR Perception System costs 1/500th the cost of mechanical LiDAR and provides higher resolution and better field of view. With intelligence perception algorithms, it can clearly recognize small objects, such as railings and fences and works in all weather conditions and at night and has no blind zone. It is automotive grade and has longer detection distance, making it ideal for autonomous solutions.” Another judge said it is “the best performer in the category and will take autonomous driving to the next level.” And another judge concluded, the RoboSense System is “Innovative technology which cuts costs and improves performance greatly. This has everything in its favor and offers the complete package for next generation vehicles.”
More than 3,800 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. The American Business Awards are the U.S.A.’s premier business awards program. More than 200 professionals worldwide participated in the judging process to select this year’s Stevie Award winners.
“We are honored to be recognized by the prestigious American Business Awards for our innovative LiDAR technology that propels autonomous driving into mass production for use by everyone, from passenger cars, RoboTaxis, logistics vehicles, shuttle buses, and more,” said Mark Qiu, Co-Founder & COO, RoboSense.
“The nominations submitted to The 2019 American Business Awards were outstanding. They illustrate the continued vibrancy of innovation and high level of achievement across the American economic landscape,” said Michael Gallagher, president and founder of the Stevie Awards.
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading LiDAR environment perception solutions provider and developer of LiDAR hardware, AI point cloud algorithms, and IC designs. Founded in 2014, RoboSense has over 500 employees in six locations, including the U.S., Shenzhen, Beijing, Shanghai, and Germany. Focusing on the strategic deployment of smart sensor systems, RoboSense has developed a variety of application solutions based on LiDAR hardware technologies and algorithms. In five years, RoboSense has already released 18 products and technical solutions, and has applied for more than 400 patents.
RoboSense has a variety of product lines, including MEMS solid-state LiDAR and Mechanical LiDAR smart sensor systems. Customers include the world’s major autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers. RoboSense LiDAR solutions have been widely used in various application scenarios, such as self-driving logistics vehicles, buses, passenger cars, and more. For more information, see https://www.robosense.ai.
About the Stevie Awards
Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom